Proposed Golimumab Biosimilar AVT05 Meets Primary Endpoints in Moderate to Severe RA

At the end of the trial, the study met its primary outcome, indicating therapeutic equivalence between the biosimilar (AVT05) and reference golimumab.

Related Keywords

Robert Wessman ,Momna Ali ,Cameroni Alvotech , ,Rheumatology Informatics System ,Clinical Disease Activity Index ,Disease Activity ,Rheumatoid Arthritis ,Globenewswire News ,